Table 3 Clinical characteristics and respiratory evolution of children with thymic stromal lymphopoietin (TSLP) measured at admission for bronchiolitis according todetectable vs. non-detectable TSLP
From: Nasal TSLP and periostin in infants with severe bronchiolitis and risk of asthma at 4 years of age
Detectable TSLP (N = 27) N(%) | Non-detectable TSLP (N = 195) N(%) | p-value | |
|---|---|---|---|
Male sex | 16(59%) | 111(57%) | 0.818 |
Age at admission < 6 months | 19(91%) | 107(72%) | 0.06 |
ICU admission | 3(12%) | 5(2.5%) | 0.02 |
Premature birth | 3(11.5%) | 21(12%) | 0.992 |
Atopic dermatitis | 13(48%) | 81(42%) | 0.529 |
Siblings with asthma | 10(40%) | 24(15%) | 0.002 |
Passive tobacco exposure | 10(40%) | 50(30%) | 0.197 |
Positive viral detection | 23(85%) | 168(86%) | 0.620 |
Viral coinfection | 10(43%) | 45(26%) | 0.09 |
RSV infection | 20(83%) | 133(71%) | 0.220 |
RV infection | 9(39%) | 45(27%) | 0.211 |
RSV + RV coinfection vs. RSV single infection | 8(42%) | 28(21%) | 0.04 |
RSV + RV coinfection vs. RV single infection | 8(90%) | 28(62%) | 0.121 |
Recurrent wheezing | 20(74%) | 141(72%) | 0.847 |
Hospitalization for asthma | 9(33%) | 36(19%) | 0.08 |
Asthma maintenance treatment | 15(56%) | 68(35%) | 0.04 |
Inhaled corticosteroids treatment | 10(38.5%) | 41(22%) | 0.07 |
Montelukast | 9(35%) | 27(15%) | 0.01 |
Inhaled corticosteroids + montelukast | 6(23%) | 17(9%) | 0.03 |
Recurrent wheezing | 20(74%) | 141(72%) | 0.847 |
Admission for asthma | 9(33%) | 36(19%) | 0.07 |
Ever wheezing | 22(85%) | 150(79%) | 0.501 |
Wheezing in the past 12 months | 6(23%) | 72(38%) | 0.140 |
Ever asthma | 6(23%) | 43(23%) | 0.878 |
Wheezing after exercise | 3(11%) | 21(11%) | 0.927 |
Dry cough at night | 3(11%) | 25(13%) | 0.832 |